Evidence map›Paper›PMID 29069511›Full record

SynthesisSchizophrenia bulletin2018

Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis.

Daniel J Devoe, Aaron Peterson, Jean Addington

Erratum issuedOpen access · bronzeAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Schizophrenia bulletin, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 12 pooled it
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 12 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. EPA guidance on assessment of negative symptoms in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2021
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Interventions for prodromal stage of psychosis.The Cochrane database of systematic reviews · 2019
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Trial
  15. Impact of early social isolation on social circuits and behavior: relevance to schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Daniel J DevoeHotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Alberta, Canada.
Aaron PetersonHotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Alberta, Canada.
Jean AddingtonHotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Alberta, Canada.
University of Calgary · CA

Funding

3 Cognitive Behavioral Social Skills Training for Youth at Risk of PsychosisR01MH105178 · NIMH · UNIVERSITY OF CALGARY · PI ADDINGTON, JEAN M · 2014 to 2018
$1.4M
NIMH NIH HHS R01 MH105178
6 · The paper itself

Abstract

Objective: Youth at clinical high risk (CHR) for psychosis often demonstrate significant negative symptoms, which have been reported to be predictive of conversion to psychosis and a reduced quality of life but treatment options for negative symptoms remain inadequate. Therefore, we conducted a systematic review and network meta-analysis of all intervention studies examining negative symptom outcomes in youth at CHR for psychosis. Method: The authors searched PsycINFO, Medline, Embase, CINAHL, and EBM from inception to December 2016. Studies were selected if they included any intervention that reported follow-up negative symptoms in youth at CHR for psychosis. Treatment comparisons were evaluated using both pairwise and network meta-analyses. Due to the differences in negative symptom scales the effect sizes were reported as the standardized mean difference (SMD). Results: Of 3027 citations, 32 studies met our inclusion criteria, including a total of 2463 CHR participants. The null hypothesis was not rejected for any of the 11 treatments. N-methyl-D-aspartate-receptor (NMDAR) modulators trended toward a significant reduction in negative symptoms compared to placebo (SMD = -0.54; 95% CI = -1.09 to 0.02; I2 = 0%, P = .06). In respective order of descending effectiveness as per the treatment hierarchy, NMDAR modulators were more effective than family therapy, need-based interventions, risperidone, amisulpride, cognitive behavioral therapy, omega-3, olanzapine, supportive therapy, and integrated psychological interventions. Conclusions: Efficacy and effectiveness were not confirmed for any negative symptom treatment. Many studies had small samples and the majority were not designed to target negative symptoms.

Indexed as

AdolescentAdultAntipsychotic AgentsFemaleHumansMaleOutcome Assessment, Health CarePsychotherapyPsychotic DisordersSchizophreniaYoung AdultAntipsychotic Agents

Identifiers

PMID29069511
PMCPMC6007754
OpenAlexW2765822046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.